Though the Ragon Institute started by studying HIV, we quickly expanded to other global infectious diseases. Our expansion began with tuberculosis, which often affects people living with HIV, and soon moved to the influenza virus, which affects millions globally every year.
Our BL3 core allows us to work with many infectious pathogens safely, including tuberculosis. Our researchers, from engineers to virologists, study these diseases with the goal of developing better prevention, understanding, and treatment to achieve a global impact.
Current projects in this area include understanding the mechanisms of tuberculosis infections, developing a universal flu vaccine, and understanding how tuberculosis and HIV interact when co-infecting the same patient.
Visit our secure online donation page on the Massachusetts General Hospital site to donate online. Donations are also accepted via mail; please address them to:
Ragon Institute of Mass General, MIT, and Harvard
400 Technology Square
Cambridge, MA 02139
Mucosal Immunology, Microbiome, HIV, Clinical Research, Emerging Infectious Diseases
Douglas S. Kwon, MD, PhD
The Ragon is committed to the study of emerging infectious diseases, such as Ebola, Zika, SARS/MERS, which have a devastating global impact.
Though the Ragon Institute started by studying HIV, we quickly expanded to other global infectious diseases.
The Ragon’s research creates knowledge from our collaborative, cross-disciplinary approach, breaking down the silos of academia.
